Figure 7. 3-deaazadenosine improves the engraftment of umbilical cord blood cells.

a, Frequency of long-term culture initiating cells of cord blood-derived CD34+ cells upon treatment with 10 μM 3DA or the vehicle (DMSO). The number of cells that needed to be plated for one LTC-IC to develop is indicated. Identically coloured circles indicate paired experimental and control samples that originate from the same cord. Statistical significance was determined using two-tailed Wilcoxon matched-pairs signed rank test (n = 8 independent experiments). b, Experimental design for the cord blood RNA-seq experiment. c, GSEA signature for oxidative stress-induced senescence. d, GSEA signature for Hay bone marrow CD34+ hematopoietic stem cells (HSC). e, Experimental design for the cord blood transplant experiment. f, Cord blood derived human hematopoietic stem and progenitor (CD34+) cells were treated at day 1, 4 and 7 with 10 μM 3DA or DMSO and analysed before xenotransplantation at day nine. Changes in cell surface markers CD34 and CD38 were analyzed by flowcytometry. The percentage of CD34+CD38-cells is shown. Data are represented as mean ± SD. g, 1.5x10⁶ cells from the experiment described in c. were transplanted into NSG mice. The engraftment of human (CD45+) cells in peripheral blood is significantly higher in the 3DA treated group. Data are represented as mean. For f and g, each shape (open cicle, closed circle, star, square or triangle) represents a different cord blood sample. Each shape is the average of 2-3 mice transplanted with that cord blood sample (n = 4 independent cord blood samples). Statistical significance was determined using two-tailed pared t test.